Immunotherapy Tablets For Dust Mite Allergy Reduce Asthma Risk
Are allergy shots going out of favor. This is good news for patients and bad news for allergist who make most of their income out of allergy shots for at least 3 years. The tablets are much more convenient however the price might be very high!
In 2014, the Food and Drug Administration approved Oralair for grass allergies. It was the first sublingual allergy immunotherapy tablet approved for use in the United States. It then approved Grastek, also for grass allergies, and Ragwitek, for ragweed allergies.
FDA Launches Campaign Against Teenage Smokeless Tobacco Use
Government health officials will team up with minor league baseball as part of a new $36 million campaign to discourage rural teenagers from using chewing tobacco.
E-cigarette Use Continued to Rise Among Young US Teenagers
About 5 percent of middle-school students reported using e-cigarettes in 2015, up from about 4 percent in 2014, according to data from the CDC and prevention. That is a substantial increase from 2011, when less than 1 percent of middle schoolers used the devices.
USPSTF: COPD screening in asymptomatic adults offers no benefit
Similar to 2008, the USPSTF did not find evidence that screening for COPD in asymptomatic persons improves health-related quality of life, morbidity, or mortality. The USPSTF determined that early detection of COPD, before the development of symptoms, does not alter the course of the disease or improve patient outcomes. The USPSTF concludes with moderate certainty that screening for COPD in asymptomatic persons has no net benefit.
Antacids Don’t Improve Pulmonary Fibrosis Outcome
The debate continues!!!
In the newly published analysis, which included pooled data from the placebo groups of three pirfenidone studies, researchers analyzed the effects of antacid treatment use from baseline on pulmonary function, exercise tolerance, survival, hospital admission, and adverse events over the course of a year.